12月10日的资金流向数据方面，主力资金净流出204.73万元，占总成交额2.77%，游资资金净流入31.46 万元，占总成交额0.43%，散户资金净流入173.27万元，占总成交额2.34%。 近5日资金流向一览见下表： 证券之星消息，截至2025年12月10日收盘，心脉医疗(688016)报收于91.62元，上涨0.22%，换手率 0.66%，成交量8110.0手，成交额7391.49万元。 心脉医疗2025年三季报显示，前三季度公司主营收入10.15亿元，同比上升4.66%；归母净利润4.29亿 元，同比下降22.46%；扣非净利润3.72亿元，同比下降25.8%；其中2025年第三季度，公司单季度主营 收入3.0亿元，同比上升64.68%；单季度归母净利润1.14亿元，同比下降23.63%；单季度扣非净利润1.02 亿元，同比下降11.84%；负债率15.85%，投资收益1160.33万元，财务费用-785.84万元，毛利率 70.4%。心脉医疗（688016）主营业务：主动脉及外周血管介入医疗器械的研发、生产和销售。 该股最近90天内共有9家机构给出评级，买入评级7家，增持评级2家；过去90天内机构 ...

证券之星消息，截至2025年12月8日收盘，心脉医疗(688016)报收于93.1元，下跌0.09%，换手率 0.72%，成交量8897.0手，成交额8306.01万元。 12月8日的资金流向数据方面，主力资金净流入319.21万元，占总成交额3.84%，游资资金净流入379.45 万元，占总成交额4.57%，散户资金净流出698.66万元，占总成交额8.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 93.10 -0.09% | | 319.21万 | 3.84% | 379.45万 | 4.57% | -698.66万 | -8.41% | | 2025-12-05 | 93.18 | 1.28% | -442.24万 | -5.52% | -102.43万 | -1.28% | 544.67万 | 6.80% | | 2025-12-04 | | 92. ...

该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月5日收盘，心脉医疗(688016)报收于93.18元，上涨1.28%，换手率 0.7%，成交量8673.0手，成交额8010.91万元。 12月5日的资金流向数据方面，主力资金净流出442.24万元，占总成交额5.52%，游资资金净流出102.43 万元，占总成交额1.28%，散户资金净流入544.67万元，占总成交额6.8%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-05 | 93.18 | 1.28% | -442.24万 | -5.52% | -102.43万 | -1.28% | 544.67万 | - 6.80% | | 2025-12-04 | | 92.00 -0.12% | - -837.21万 | -8.37% | -82.97万 | -0.83% | 920.17万 | 9.20% | ...

证券日报网讯12月1日，心脉医疗在互动平台回答投资者提问时表示，根据公司2025年第三季度报告， 截至2025年9月30日，公司股东总数为15，990户。 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

截至2025年11月21日收盘，心脉医疗（688016）报收于91.25元，较上周的102.25元下跌10.76%。本 周，心脉医疗11月17日盘中最高价报102.94元。11月21日盘中最低价报91.23元。心脉医疗当前最新总市 值112.48亿元，在医疗器械板块市值排名31/126，在两市A股市值排名1611/5167。 交易信息汇总：心脉医疗11月18日发生1笔折价18.73%的大宗交易，合计成交2970.3万元 交易信息汇总 11月18日心脉医疗现1笔折价18.73%的大宗交易，合计成交2970.3万元 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 ...

Core Viewpoint - In Q3 2025, the company's performance met expectations, with overseas business maintaining rapid growth, while domestic business rebounded quickly against last year's low base. Looking ahead to Q4 2025, revenue is expected to show rapid growth, and profits are anticipated to turn from loss to profit. For 2026, while external peripheral intervention and overseas business are expected to continue high growth, uncertainties exist in the domestic large stent business due to centralized procurement [1][4]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.015 billion yuan, a year-on-year increase of 4.66%. The net profit attributable to the parent company was 429 million yuan, a decrease of 22.46% year-on-year, while the net profit excluding non-recurring items was 372 million yuan, down 25.80% year-on-year. The earnings per share (EPS) was 3.54 yuan [2][3]. - In Q3 alone, the company reported revenue of 300 million yuan, a year-on-year increase of 64.68%, with a net profit of 114 million yuan, down 23.63% year-on-year. The net profit excluding government subsidies and other investment income increased by 60% year-on-year [3]. Regional Performance - Domestic product sales growth remained above 20% in the first three quarters, but revenue was flat year-on-year due to price governance and centralized procurement impacts. In Q3 2025, domestic revenue showed positive growth year-on-year after a 17.24% decline in the first half of the year. Overseas business revenue grew over 65% year-on-year, increasing its share of total revenue to 18% [3][4]. Future Outlook - In Q4 2025, revenue is expected to grow rapidly, and profits are projected to turn positive. For 2026, while external peripheral intervention and overseas business are likely to maintain high growth, uncertainties in the domestic large stent business due to centralized procurement may impact performance. Excluding the effects of centralized procurement, revenue and profits are expected to recover rapidly based on this year's low base [4][9]. - The company is enhancing its global layout and product innovation, with a focus on meeting clinical market demands and increasing R&D investment to build a competitive product portfolio in the fields of aortic intervention, peripheral intervention, and tumor intervention [1][5]. R&D and Product Development - The company is progressing well with its R&D projects, including the Hector thoracic aortic multi-branch stent, which has completed clinical enrollment for the first patient in a domestic multi-center trial. Other products like the Aegis II abdominal aortic stent and IBD iliac branch stent are also advancing as planned [5]. - The company has a strong pipeline of products expected to be approved and launched in the coming year, including several key products in the peripheral business [5][6]. International Expansion - The company has been expanding its overseas business, covering regions such as the Middle East, Asia-Pacific, and South America, with a recent acquisition enhancing its presence in Europe. As of October, the company has added 11 new overseas registrations and expanded into 7 new countries [6][7]. - The Castor and Cratos branched aortic stents are experiencing good growth in Europe, South America, and Asia-Pacific, with the Cratos stent expected to receive approval in 2026. The Hector stent has already received a custom certificate in the EU and is now being launched in the market [7]. Operational Efficiency - The company's gross margin for Q3 was 73.28%, an increase of 2.43 percentage points year-on-year, attributed to improved production efficiency and reduced material costs. The company aims to maintain a gross margin above 70% for the year [8]. - The company’s operating cash flow for the first three quarters was 363 million yuan, a decline of 3.26% year-on-year. Accounts receivable turnover days increased by 42.13 days to 91.52 days, while inventory turnover days decreased by 44.57 days to 228.85 days [8].

Core Viewpoint - A block trade of 375,200 shares of Xinmai Medical occurred on November 18, with a transaction value of 29.703 million yuan, reflecting a discount of 18.73% compared to the closing price of the day [2] Summary by Category Block Trade Details - The transaction volume was 375,200 shares, with a transaction amount of 29.703 million yuan and a transaction price of 79.16 yuan [2] - The transaction price represented an 18.73% discount relative to the closing price of 97.40 yuan on the same day [2] - The buyer was CITIC Securities Co., Ltd., Shanghai Yingkou Road Securities Business Department, and the seller was Huabao Securities Co., Ltd., Shanghai Dalian Road Securities Business Department [2] Stock Performance - Xinmai Medical's closing price on November 18 was 97.40 yuan, down 1.57% from the previous day [2] - The stock had a turnover rate of 0.97% and a total trading volume of 117 million yuan for the day [2] - Over the past five days, the stock has declined by 3.47%, with a total net inflow of funds amounting to 9.667 million yuan [2] Margin Trading Data - The latest margin financing balance for Xinmai Medical is 500 million yuan, which has decreased by 18.183 million yuan over the past five days, representing a decline of 3.51% [2] Company Background - Shanghai MicroPort Xinmai Medical Technology (Group) Co., Ltd. was established on August 17, 2012, with a registered capital of 1.2326 billion yuan [2]

11月18日，心脉医疗大宗交易成交37.52万股，成交额2970.3万元，占当日总成交额的20.25%，成交价 79.16元，较市场收盘价97.4元折价18.73%。 | IN 275 Millio Julia, 11 EU FESA | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | 卖出营业部 是否为专场 | | 025-11-18 | 心酵医疗 | 688016 | 79.16 2970.3 | 37.52 | 東證書貸生多醫出 | 菜酒店餐饮酒酒店 ка | ...

Core Viewpoint - Shanghai MicroPort MedBot (688016) held its first extraordinary general meeting of shareholders on November 14, 2025, where significant resolutions were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [2][4]. Trading Information Summary - As of November 14, 2025, the stock closed at 102.25 yuan, with a slight increase of 0.25% - The turnover rate was 1.65%, with a trading volume of 20,400 lots and a total transaction value of 212 million yuan - On the same day, the net outflow of main funds was 4.6228 million yuan, accounting for 2.18% of the total transaction value, while retail funds saw a net outflow of 6.6637 million yuan, representing 3.15% of the total transaction value [1][4]. Company Announcements Summary - The extraordinary general meeting approved three key resolutions: the cancellation of the supervisory board and amendments to the articles of association, the revision and addition of certain management systems, and the purchase of liability insurance for directors and senior management [2][4]. - The meeting was convened by the board of directors and chaired by Jonathan Chen, utilizing a combination of on-site and online voting methods, with the results deemed legally valid [2]. - Additionally, a workers' representative meeting was held on the same day, electing Yuan Zhenyu as the employee representative director for the third board of directors, with his term starting immediately upon approval [3].